| Biomarker ID | 801 |
| PMID | 22071976 |
| Year | 2011 |
| Biomarker | LTB; OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCA; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCA; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1; CAMP; ELA2; DEFA4; DEFA3; DEFA1; DEFA1; DEFA1; DEFA1; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Blood |
| Subjects | Humans |
| Regulation | Downregulated: [LTB (1.03 fold)] ; Upregulated (1.04- 2.87 fold): [OLR1; CEACAM1; ARG1; MYL4; ALAS2; SLPI; SELENBP1; SNCAe; AZU1; HMGXB4; RNASE3; HBQ1; MMP9; GYPE; SNCAe; EPB42; HP; IFIT1L; BPI; CEACAM6; MPO; OLFM4; HBM; ALAS2; CEACAM8; CA1; HBD; LCN2; CTSG; DEFA1e; CAMP; ELA2; DEFA4; DEFA3; DEFA1e; DEFA1e; DEFA1e; DEFA1e;] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(OLR1):-PPAR signaling pathway,Cell surface interactions at the vascular wall,Phagosome,Hemostasis pathway |
| Experiment | Long-term survivors (survived for >900 days) Vs Short-Term survivors (died within 300 days) - Postvaccination |
| Type of Biomarker | Prognostic |
| Cohort | 164 patients with metastatic castration-resistant prostate cancer were chosen. Out of which 40 were chosen as control set: (survived for >900 days (long-term survivors n =20) or died within 300 days (short-term survivors n=20). The rest are chosen as validation set. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p< 0.008 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Personalised Peptide vaccines were given to patients |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on Independent Patient Cohort |
| Technical Name | LTB, OLR1, CEACAM1, ARG1, MYL4, ALAS2, SLPI, SELENBP1, SNCA, AZU1, HMGXB4, RNASE3, HBQ1, MMP9, GYPE, SNCA, EPB42, HP, IFIT1L, BPI, CEACAM6, MPO, OLFM4, HBM, ALAS2, CEACAM8, CA1, HBD, LCN2, CTSG, DEFA1, CAMP, ELA2, DEFA4, DEFA3, DEFA1e |